The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
UK Supreme Court; Actavis; Eli Lilly; patent; Alimta; English Court of Appeal; pemetrexed